RIFINAH Italia - italiensk - AIFA (Agenzia Italiana del Farmaco)

rifinah

sanofi s.r.l. - rifampicina, associazioni - rifampicina, associazioni

RIFATER Italia - italiensk - AIFA (Agenzia Italiana del Farmaco)

rifater

sanofi s.r.l. - rifampicina, pirazinamide e isoniazide - rifampicina, pirazinamide e isoniazide

Verzenios Den europeiske union - italiensk - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - neoplasie al seno - agenti antineoplastici - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

FEMARA Italia - italiensk - AIFA (Agenzia Italiana del Farmaco)

femara

novartis farma s.p.a. - letrozolo - letrozolo

Fareston Den europeiske union - italiensk - EMA (European Medicines Agency)

fareston

orion corporation - toremifene - neoplasie al seno - terapia endocrina - trattamento ormonale di prima linea del carcinoma mammario metastatico ormone-dipendente nei pazienti in postmenopausa. fareston non è raccomandato per i pazienti con il recettore per gli estrogeni negativi tumori.

AROMASIN Italia - italiensk - AIFA (Agenzia Italiana del Farmaco)

aromasin

pfizer italia s.r.l. - exemestane - exemestane